Replies to post #131630 on Biotech Values

[DewDiligence]

Today, GILD regained 2/3 of yesterday’s price drop. Perhaps the preponderance of survey opinion on this board was unduly negative toward the VRUS deal (#msg-69242677).

[DewDiligence]

Blair analyst, Katherine Xu says PSI-7977 plus VRUS’ “other” HCV drugs will attain peak annual sales of $14B (!):

http://finance.yahoo.com/news/Sector-Snap-Hepatitis-C-apf-499222132.html?x=0

Not helping Xu’s credibility is the fact that she lowered the price target on VRTX from $57 to $45. (The stock is currently trading at $27 and change.)